The following trials have been completed: 

Janssen Ventura 2: 67953964MDD3002:  A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy.

Cassava Sciences PTl-125-06: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76 Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilamin Subjects with Mild to

Moderate Alzheimer’s Disease.

GemVax GV1001-AD-CL2-007: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate AD.

Biogen 221AD305: A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease.

Avanir 17-AVP-786-305: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

Biogen 221AD304: Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer’s disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205. 

Eli Lilly I5T-MC-AACI: A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2). Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease.

Otsuka Pharmaceutical Development & Commercialization, Inc. 331-14-213 A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type. Agitation in Alzheimer’s Disease.

Alzheon Apollo E4 ALZ-801-AD301: A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype.

Shanghai Green Valley Pharmaceutical Co. GV971-007: A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer’s Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory). Mild Alzheimer’s Disease to Moderate Alzheimer’s Disease. 

Liva Nova Recover LND 300:  A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects with Treatment-Resistant Depression. Treatment Resistant Depression.

UCB AH0003 – A Patient - and Investigator Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants with Prodromal to Mild Alzheimer’s disease (AD), Followed by an Open Label Extension Period. Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease. 

Eli Lilly I8G-MC-LMDC – Assessment of Safety, Tolerability and Efficacy of LY3303560 in Early Symptomatic Alzheimer’s Disease – Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

I5T-MC-AACG – Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination with LY3202626 in Early Symptomatic Alzheimer’s Disease – Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

Eisai E2609-G000-301 – A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects with Early Alzheimer’s Disease. (Closed for screening) – Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease.

Tetra – BPN14770-CNS-201 – A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Stages Alzheimer’s Disease – Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

Acadia045 – ACP-103-045 – A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis (Hallucinations and/or Delusions) – Symptoms of Psychosis for Any Related Diagnosis of Dementia

Avanir 17-AVP-786-305 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo, Parallel-Design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (deudextromethorpan hydrobromide [d6-DM / quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type. Agitation in Alzheimer’s Disease

Avanir 15-AVP-786-303 – A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6]- destromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q] for the treatment of Agitation in Patients with Dementia of the Alzheimer’s Type. Open Label for Agitation in Alzheimer’s Disease

Novartis CCNP520A2202J – A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (AD) – Preventive study

Biogen 221AD302 – A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease. Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

CREAD BN 29552 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety of crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease. Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

Acadia ACP-103-033 – A 52 week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease.

Acadia ACP-103-032 – Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease.

Eli Lilly I8D-MC-AZET – A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (The DAYBREAK Study). Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease

Avanir 15-AVP-786-301 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of AV-786 (deuterated [d6] – dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q] for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type.

“A Multicenter, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis with Infusion of Albutein® Combined with Flebogammadif® in Patients with Mild-Moderate Alzheimer’s Disease” (the “Study”), bearing Protocol No. IG 1002 (AMBAR)

Study number: 14863A Protocol title: “Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3”

Protocol H8A-MC-LZAX “ Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo” (EXPEDITION-3)

ELND005-AG201 “A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer’s Disease”

“A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-923 (dextromethorphan/quinidine) for the treatment of symptoms of agitation in patient with Alzheimer’s disease”

An open label, multicenter study, evaluating the safety and imaging characteristics of F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer's disease.
Avid Radiopharmaceuticals

A Randomized, 18-week, placebo-controlled, double-blind, parallel group study of the safety and efficacy of PF-052212377 (SAM-760) in subjects with mild-to-moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
Pfizer Pharmaceuticals

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc.

A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Elan Pharma International Limited

= Trial is Closed